Related Experiment Video
Updated: Mar 16, 2026
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
How abciximab might be clinically useful
Coşkun Usta1, Nur Tükel Turgut1, Aslı Bedel1
1Department of Pharmacology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Insights
Glycoprotein (GP) IIb/IIIa inhibitors were vital for acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). Current therapy shifts away from these agents due to effectiveness and adverse effects, necessitating careful benefit-harm evaluation.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Background:
- Platelet aggregation, mediated by glycoprotein (GP) IIb/IIIa receptors, is central to coronary artery thrombus formation.
- GP IIb/IIIa inhibitors (GPI) significantly reduced ischemic complications in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI) since the late 1990s.
Purpose of the Study:
- To review the role and current standing of GP IIb/IIIa inhibitors, specifically abciximab, in managing ACS and PCI.
- To discuss the evolving therapeutic landscape and the reasons for the shift away from GPIs in ST-segment elevation myocardial infarction (STEMI).
Main Methods:
- Literature review focusing on the clinical application and outcomes of GP IIb/IIIa inhibitors.
- Detailed examination of abciximab's efficacy and safety profile.
- Comparative analysis of GPIs with alternative therapeutic agents.
Main Results:
- While GPIs demonstrated clear clinical benefits, particularly in PCI during ACS (NSTE-ACS and STEMI), their use has declined in STEMI therapy.
- Factors contributing to this shift include evolving treatment strategies, concerns about effectiveness, and potential adverse effects like thrombocytopenia and bleeding.
- Variability exists among GPIs, with abciximab being the focus of this review.
Conclusions:
- The therapeutic utility of potent agents like GP IIb/IIIa inhibitors requires a careful balance of benefits and harms.
- Ongoing evaluation is necessary to optimize treatment strategies for ACS and PCI, considering both efficacy and safety profiles.
Abstract:
Platelet aggregation is a crucial feature in coronary artery thrombus formation and is a major causative factor in both acute coronary syndromes (ACS) and reocclusion after percutaneous coronary interventions (PCI). The glycoprotein (GP) IIb/IIIa (αIIbβ3) integrin receptor is the pivotal mediator of platelet aggregation. In late 1990s, the introduction of GP IIb/IIIa inhibitors (GPI) was associated with a reduction of ischemic complication, and a clear clinical benefit in PCI during ACS, for both non ST-elevation (NSTE) and ST-segment elevation myocardial infarction (STEMI). The currently available GPI (abciximab, eptifibatide and tirofiban) tended to be replaced in the current therapy of STEMI by different agents and this is in part related to the effectiveness and to the potential adverse effects (thrombocytopenia and bleeding). There might be a certain level of variability among these agents and here we have reviewed only abciximab in detail. Interestingly, however, the story may not be entirely different from that of positive inotropic agents in the context of acute ischemia where the potent action to sustain left ventricular function had an arrhythmogenic counterpart to evaluate and take into consideration and therefore therapeutically it will always be necessary to weigh benefits and harms if actions are expected by relatively potent agents.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
